anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/JP88/00483 Sec. 371 Date Jun. 9, 1988 Sec. 102(e) Date Jun. 9, 1988 PCT Filed May 23, 1988 PCT Pub. No. WO89/05635 PCT Pub. Date Jun. 29, 1989.Solid medicament forms, such as granules, beads, tablets, are first coated with a hot aqueous dispersion of a cellulose ether, which is soluble in cold water but insoluble in hot water, and then subjected to a wax treatment with heating to form a masking layer of the wax. Different from the coating film of a cellulose ether formed by using an aqueous or organic solution of the cellulose ether, the coating film formed by using the aqueous dispersion of the cellulose ether has a porous structure so that the amount of the wax deposited in the wax treatment is much larger than in the prior art methods to exhibit a high effect of masking the bitterness of the ingredient contained in the medicament form.
BACKGROUND: Dystonia is a hyperkinetic movement disorder with key motor network dysfunction implicated in pathophysiology. The UK Biobank encompasses > 500,000 participants, of whom 42,565 underwent brain MRI scanning. This study applied an optimized pre-processing pipeline, aimed at better accounting for artifact and improving data reliability, to assess for grey and white matter structural MRI changes between individuals diagnosed with primary dystonia and an unaffected control cohort.
METHODS: Individuals with dystonia (n = 76) were identified from the UK Biobank using published algorithms, alongside an age- and sex-matched unaffected control cohort (n = 311). Grey matter morphometric and diffusion measures were assessed, together with white matter diffusion tensor and diffusion kurtosis metrics using tractography and tractometry. Post-hoc Neurite Orientation and Density Distribution Imaging (NODDI) was also undertaken for tracts in which significant differences were observed.
RESULTS: Grey matter tremor-specific striatal differences were observed, with higher radial kurtosis. Tractography identified no white matter differences, however segmental tractometry identified localised differences, particularly in the superior cerebellar peduncles and anterior thalamic radiations, including higher fractional anisotropy and lower orientation distribution index in dystonia, compared to controls. Additional tremor-specific changes included lower neurite density index in the anterior thalamic radiations.
CONCLUSIONS: Analysis of imaging data from one of the largest dystonia cohorts to date demonstrates microstructural differences in cerebellar and thalamic white matter connections, with architectural differences such as less orientation dispersion potentially being a component of the morphological structural changes implicated in dystonia. Distinct tremor-related imaging features are also implicated in both grey and white matter.
A community-based CBCBT is tested for patients living with diabetes(DM) and subclinical depression. The program includes both face-to-face group sessions and individual telephone sessions. The aim of the current study is to evaluate the efficacy of a mixed mode CBCBT in reducing depressive symptoms and enhancing adherence among adults with DM and subclinical depression. The intervention program consists of three components: 1) eight weekly sessions of face-to-face interventions, 2) four weekly consolidation individual telephone calls and 3) three monthly individual follow-up phone calls.

This is a prospective randomized two-armed intervention study. The CBCBT intervention will be compared with enhanced treatments usual (ETAU) using a single blinded randomized design. The intervention will be delivered by qualified health care professional (e.g. clinical psychology/ social worker/ nurse counsellor) who have had some training in CBCBT in the initial training.
Detergent compositions contain a non-cationic detergent and a cellulose ether compositions prepared by mixing a water-soluble hydroxy-propyl methyl cellulose and/or a water-soluble alkali metal carboxy methyl cellulose salt (a) with a homogeneous solvent comprising a saturated polyhydric alcohol (b) containing from 5 to 8 carbon atoms per molecule, each carbon atom having one hydroxyl substituent such as sorbitol, and a saturated aliphatic monohydric alcohol (c) having from 1 to 3 carbon atoms per molecule and water (d), the weight ratio of (a) to the sum of (b) and (c) being from 0.1:1 to 0.5:1 and the proportion of water being up to 40% by weight of the composition.  The cellulose ether may be hydroxy-propyl methyl cellulose having a methoxyl content between 25 and 32% and a hydroxypropyl content between 2 and 10% by weight.  The non-cationic detergent may be a sulphate, a sulphonate, a polypeptide condensate, an alkylolamide, soap or amide of amino-acid.  A shampoo comprising the composition may contain 1 to 5% of (a), 2 to 15% of (b), 3 to 10% of (c), 35 to 75% of (d) and 5 to 35% of a water-soluble non-cationic organic detergent comprising at least predominantly anionic sulphate or sulphonate detergent.ALSO:Cellulose ether compositions are prepared by mixing a water-soluble hydroxypropyl methyl cellulose and/or a water-soluble alkali metal carboxy methyl cellulose salt (a) with a homogeneous solvent comprising a saturated polyhydric alcohol (b) containing from 5 to 8 carbon atoms per molecule, each carbon atom having one hydroxyl substituent, a saturated aliphatic monohydric alcohol (c) having from 1 to 3 carbon atoms per molecule and water (d), the weight ratio of (a) to the sum of (b) and (c) being from 0.1:1 to 0.5:1 and the proportion of water being up to 40% by weight of the composition. The cellulose ether may be hydroxypropyl methyl cellulose having a methoxyl content between 25 and 32% and a hydroxypropyl content between 2 and 10% by weight.  The polyhydric alcohol may be sorbitol.  The monohydric alcohol may be ethyl alcohol.  The composition may contain a detergent such as an anionic sulphate and/or sulphonate. A detergent may be mixed with the cellulose ether dispersion, and to the mixture may be added an aqueous solution of the same or a different detergent to form a clear gel, the aqueous solution of detergent comprising from 50 to 80% of the clear gel.  A shampoo comprising the composition may contain 1 to 5% of (a), 2 to 15% of (b), 3 to 10% of (c), 35 to 75% of (d) and 5 to 35% of a water-soluble non-cationic organic detergent comprising at least predominantly anionic sulphate or sulphonate detergent.
They are produced by applying Gold-wire process to the WaveOne (WO) system. The WOG file system exhibits repetitive back-and-forth mutual 'reciprocation' motion during preparation, in contrast to the continuous rotational motion. While rotating 150° counterclockwise during the reciprocating motion, clockwise It turns 30° in the direction of, and after 3 cycles, it completes 1 full cycle. Thus, it contributed positively to the file reaching the apical without applying excessive pressure, increasing the cutting efficiency, and accelerating the coronal movement of the debris. Small (yellow-20/0.07), WO Primary (red-25/0.07), and WOG Medium (green-35/0.06) files were used with the appropriate speed and torque values recommended by the manufacturer (300 rpm and 2.0 Ncm) by applying crown down technique. WOG files were operated in a reciprocating motion (150° counterclockwise, 30° clockwise).
BACKGROUND: Urinary incontinence (UI) is a common complication after radical prostatectomy (RP). It has a great influence on the postoperative quality of life of patients. This study aims to explore the clinical efficacy of low-frequency electrical pulse acupoint stimulation combined with pelvic floor muscle exercise in the treatment of UI after RP.
METHODS: The clinical data of 129 patients with UI after receiving RP in our hospital from July 2020 to July 2023 were retrospectively analysed. A total of 65 patients who received pelvic floor muscle exercise from July 2020 to January 2022 were set as the reference group. Of these patients, four were excluded, resulting in the inclusion of 61 cases. A total of 64 patients who received low-frequency electrical pulse acupoint stimulation combined with pelvic floor muscle exercise from February 2022 to July 2023 were classified into the observation group. Of these patients, four were excluded, and 60 cases were finally included. SPSS 23.0 was used to analyse the use of urine pads, recovery time of urinary control and improvement of urination in the two groups.
RESULTS: Before treatment, no significant difference existed in the use of urine pads, urination condition, maximum flow rate, maximum cystometric capacity, maximum urethral closure pressure, abdominal leak point pressure and scores on Short-Form-36 Health Survey (SF-36) in both groups (p > 0.05). After treatment, the observation group had significantly lower use of urinary pads, urination frequency and leakage times; Significantly shorter recovery time of urinary control (p < 0.05); And significantly higher maximum flow rate, maximum cystometric capacity, maximum urethral closure pressure, abdominal leak point pressure and SF-36 scores than the reference group (p < 0.05).
CONCLUSIONS: The combination of low-frequency electrical pulse acupoint stimulation and pelvic floor muscle exercise can improve clinical symptoms, shorten the recovery time of urinary control and improve urodynamics and quality of life in patients with UI after RP.
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to neurology and reflexotherapy, and can be used to treat delayed development in patients with autism spectrum disorders. Nakatani is diagnosed and biologically active points of classical meridians to be treated are selected, including control points and collar zone points, auricular points, as well as extra-meridian points located in projections on scalp of brain stem, frontal lobes, areas of cerebral cortex, including motor zones, speech zones of Broca and Wernicke. Selected points, in accordance with clinical manifestations, are exposed to microelectrophoresis and micro-current reflex therapy. That is ensured by sedative exposure to direct current of negative polarity at current intensity 30–130 mcA and time of therapeutic exposure to each biologically active point of 30–120 seconds. In the tonic mode, exposure is performed by alternating supply of pulses of positive and negative polarity with duration of 1–7 seconds. Microelectrophoresis is performed with sedative drugs, including sedative herbs and bromine, as well as preparations of nootropic group based on succinic acid. Treatment is daily with the duration of one session of 30–40 minutes and total number of sessions of 15–20 per therapeutic course.EFFECT: method provides individual selection of a therapeutic regimen in various versions of excitation and speech disorders, enables extending the range of clinical manifestations to be treated, eliminating oxygen-dependent energy deficiency of cells in certain areas of the brain and achieving stable remission.12 cl, 1 tbl, 4 ex
Derivatives of n-sulfonylureas and their therapeutic use. The present invention relates to a series of compounds derived from N-suffoniureas, compounds of general formula (1), with pharmacological activity that inhibits the NLRP3 inflammasome. {IMAGE-01} The use of the compounds referred to with the general formula (I) is claimed as agents for the treatment of preferably human diseases that involve an inflammatory process, preferably mediated by what is known as an inflammasome, preferably of the type called NLRP3. Among these diseases are the so-called neurodegenerative diseases, such as Alzheimer's and Parkinson's, inflammatory diseases, metabolic diseases, autoimmune diseases and, in general, any pathology caused by the alteration of biological functions where the NLRP3 inflammasome is involved. The present invention can be framed in the field of the pharmaceutical industry.  (Machine-translation by Google Translate, not legally binding)
PURPOSE: A composition containing poly gamma glutamic acid for preventing and treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains poly gamma glutamic acid(PGA) as an active ingredient. The molecular weight of PGA is 100kDa to 15,000kDa. The composition is a pharmaceutical composition or food additive. The composition further contains pharmacologically acceptable carrier. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, external use, suppository, or sterilized injection solution.
Provided is an anti-myristoylated protein antibody or antigen-binding fragment thereof, characterized by having a light-chain variable domain consisting of CDR-L1 comprising the amino acid sequence shown by Sequence No. 1, CDR-L2 comprising the amino acid sequence shown by Sequence No. 2, and CDR-L3 comprising the amino acid sequence shown by Sequence No. 3, and/or a heavy-chain variable domain consisting of CDR-H1 comprising the amino acid sequence shown by Sequence No. 4, CDR-H2 comprising the amino acid sequence shown by Sequence No. 5, and CDR-H3 comprising the amino acid sequence shown by Sequence No. 6.
<P>PROBLEM TO BE SOLVED: To obtain a composition which is excellent in hypoglycemic action and solves the problem associated with a composition containing three active ingredients wherein the degree of contribution of the each active ingredient to the total physiological activity of the composition was unclear.  <P>SOLUTION: This composition contains Ganoderma lucidum and a root of Panax japonivus as active ingredients. Each of the active ingredients can comprise a hot-water extract and/or an extract of a water-alcohol mixture. The composition contains 15-20 pts.wt. root of Panax japonivus based on 100 pts.wt. Ganoderma lucidum.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
This study introduces a novel, cost-effective, and rapid method for identifying hemorrhage or leakage sites following postoperative deaths, a critical aspect in the context of medical malpractice litigation. The technique employs diluted ink as an injectable dye, providing an alternative to postmortem contrast imaging. The utility of this method was demonstrated through a series of three cases. In the first case, the technique successfully detected leaks within vascular structures. The second case revealed a leakage in the cystic duct, while in the third case, the method was instrumental in identifying a leak in a hollow organ situated below the gastro-esophageal junction. Given its demonstrated efficacy, this technique has been incorporated into routine practice by the forensic pathologist in the medicolegal directorate in Baghdad, Iraq.
The LEAP-M study will determine whether a 14-session program designed to provide leadership and mindfulness skills to youth of color is an effective and feasible intervention. The curriculum consists of 14 two-hour sessions delivered after school. The comparison group will take part in EnvisionIT, a college and career readiness program designed for students in grades 6 through 12. EnvisionIT aims to prepare students with essential transition skills, digital literacy, and college and career readiness. The comparison group will also have 14 two-hour group sessions. Both LEAP-M and EnvisionIT will be delivered by trained facilitators. All participants in LEAP-M and EnvisionIT will be assessed at two time points assessing program outcomes; facilitators will also complete interviews post-intervention and provide feedback on data fidelity and acceptability following each session. This record reports on the UG3 pilot phase and will be amended for a UH3 phase.
FIELD: medicine, endocrinology, biochemistry, hormones. SUBSTANCE: invention relates to zinc-free insulin crystals with diameter less 10 mcm that are useful for administration by pulmonary route. Insulin powder shows reduced trend to associate and form aggregates in dry powder and therefore it is more stable in pulmonary delivery. Invention describes also therapeutic preparative form for treatment of diabetes mellitus and method of zinc-free insulin crystals preparing. EFFECT: improved properties of insulin crystals. 21 cl, 1 dwg
This is an open-label (participants and physicians are told which treatment the participants are receiving), multi-center (when more than one hospital or medical school team work on a medical research study), single-arm study of fentanyl ITS. The study will consist of 2 phases: screening phase and an open-label treatment phase. The duration of participation in the study for an individual participant will be 72 hours. All eligible participants (who require pain treatment with strong opioids \[morphine like medications\] for at least 48 hours after an elective spine or elective orthopedic surgery) will be treated with fentanyl ITS, delivering 40 microgram (mcg) fentanyl per on-demand dose, each deliver over 10 minutes for a maximum of 6 doses per hour (240 mcg per hour) for 24 hours or a maximum of 80 doses (3.2 milligram). Participants will be analyzed for the use of intravenous (giving a medicine directly into a vein) access during postoperative pain treatment with fentanyl ITS. Participant's safety will be monitored.
Objectives: to evaluate the intra- and inter-rater reliability of the occlusion pressure generated by TF, investigate the reproducibility of TF application on different days and compare TF with traditional RFS in terms of muscle gains.

Methods: the study is divided into two stages: First stage, randomized controlled crossover clinical trial, 80 healthy individuals aged 18 to 30 years old evaluated to determine the reliability of the TF. Participants will follow one of two types of randomization, with exclusions based on health criteria. Assessments include anthropometric characteristics, determination of occlusion pressure (POT), identification of 40% and 80% of POT, flow data and arterial diameter after TF application. Statistical analysis will use the intraclass correlation index (ICC) and specific models for intra- and inter-rater analyses. Second stage, randomized controlled clinical trial with parallel groups, 34 participants will be evaluated over fifteen weeks. The initial procedures involve anthropometric assessments, POT determination, myotonometry, ultrasound, perceptual scale and 1RM test, applied to both upper limbs. Participants will perform a upper limb training protocol using RFS or TF, following myotonometric and perceptual assessments. After training, final assessments will measure the same parameters initially assessed. Statistical analysis will use normality tests, Generalized Mixed Models and effect size analysis in SPSS software, with a significance level of p\<0.05. Expected results: This study is expected to provide information on the reliability and reproducibility of TF in generating occlusion pressure. Furthermore, the investigatorsF seek to validate TF by comparing it with traditional RFS in terms of muscle gains. If effective, TF could become an affordable option to promote muscle gains, in different application scenarios.

Participants will be duly informed about the procedures and objectives of this study, and after agreeing, they will sign an informed consent form, effectively becoming part of it. In the consent form, participants will be asked if they agree to the use of their data if they choose to withdraw from the study. Participants will also be asked for permission for the research team to share relevant data with people at universities participating in the research or regulatory authorities, where relevant. The study were approved to the Research Ethics Committee of FCT/UNESP, Presidente Prudente, SP, Brazil.
In ERASMUS, 8 patients (< 1%) developed renal failure 3 to 36 months following LUTATHERA. Two of these patients had underlying renal impairment or risk factors for renal failure (e.g., diabetes or hypertension) and required dialysis.

Administer the recommended amino acid solution before, during and after LUTATHERA [see Dosage and Administration (2.3)] to decrease the reabsorption of lutetium Lu 177 dotatate through the proximal tubules and decrease the radiation dose to the kidneys. Advise patients to hydrate and to urinate frequently before, on the day of, and the day after administration of LUTATHERA.

Monitor serum creatinine and calculated creatinine clearance. Withhold dose, reduce dose, or permanently discontinue LUTATHERA based on the severity of renal toxicity [see Dosage and Administration (2.4)].

Patients with baseline renal impairment may be at increased risk of toxicity due to increased radiation exposure [see Use in Specific Populations (8.6)].
Patient management is based on clinical examination and procalcitonin assessment. From 48 hours after initiation of conservative management in the case of absence of bowel function, operative management (adhesiolysis or bowel resection) will be performed. In the event of discordance between procalcitonin values and clinical examination, management will always be based on clinical examination.
Participants will have a chance to be put on standard tuberculosis medicines (Isoniazid, Rifampicin, Ethambutol and Pyrazinamide) only. It is a combination pill pack that will be taken by mouth daily. The combination pack includes Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide which they will take for 2 months. They will only take Isoniazid and Rifampicin for the last 4 months. For this arm, they will also take Metformin hydrochloride one 500 mg tablet daily starting one week after the initiation of tuberculosis medicines, then increasing to one 500 mg table twice daily through study week-12 for a total 11 weeks of metformin exposure.
Participants receive BSSE PO QD for 7-10 days then undergo the first flashover training between day 7-10 of agent intervention. Participants then receive placebo PO QD for 7-10 days then undergo second flashover training after a washout period of 2 weeks to 3 months. Participants also undergo urine sample collection throughout the study.
To explore safe and reliable strategies and outcomes of endovascular procedures in the treatment of posterior inferior cerebellar artery (PICA) aneurysms. Retrospectively reviewed and analyzed the cases of PICA aneurysms that undergone endovascular therapy from July 2017 through January 2022 in our neurosurgical center, as well as outcomes of long-term follow-up. Total 24 cases were enrolled. Majority of the PICA aneurysms (87.5%, 21/24) presented initially with subarachnoid hemorrhage (SAH) and only 3 cases were not ruptured when they were clinically diagnosed as PICA aneurysms. The patients were endovascularly given either aneurysm occlusion with selective coils (12 cases), embolization of aneurysms and parent arteries (7 cases: 3 cases with coils and 4 cases with Onyx liquid embolic agent), or stent-assisted coiling of the aneurysms (5 cases). One patient, who had comorbidity of intracranial hemorrhage and severe cerebral vasospasm, declined further post-surgery therapy, and discharged from the hospital with anticipation of poor outcome. The rest 23 patients were followed up for 3-24 months with a recurrence rate of 17.4% (4/23). Endovascular procedure of embolizing PICA aneurysms with selective coils or stent-assisted coils is feasible, safe, and reliable. Simplified embolization of the aneurysms or occlusion of the parent artery is recommended as the first choice for the ruptured and bleeding PICA aneurysms.
Fomepizole Injection is a competitive inhibitor of alcohol dehydrogenase. The chemical name of fomepizole is 4-methylpyrazole. It has the molecular formula C4H6N2 and a molecular weight of 82.1. The structural formula is:

It is a clear to yellow liquid at room temperature. Its melting point is 25°C(77°F) and it may present as solid form at room temperature. Fomepizole is soluble in water and very soluble in ethanol, diethyl ether, and chloroform. Each vial contains 1.5 mL (1 g/mL) of fomepizole.